Phase 3 Head and Neck Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are willing and able to sign a consent form to take part in the study
- You are 40 years of age or older
- You have been diagnosed with a specific type of cancer called squamous cell carcinoma, confirmed by a tissue or cell sample, located in the mouth, throat, voice box, or lower throat area
- You are scheduled to receive standard radiotherapy with the goal of curing your cancer, either on its own, after surgery, or alongside a chemotherapy drug called cisplatin
- You are generally well enough to carry out most daily activities (your doctor will assess this)
- You are able to complete questionnaires and follow the study procedures
- You are able to answer questionnaires in Norwegian or English
- You are willing to travel to Oslo or Bergen for proton therapy if you are placed in the experimental treatment group
Who may not be able to join:
- You have an early-stage cancer of the vocal cords that has not spread to nearby lymph nodes or other parts of the body
- You have a type of cancer affecting the back of the nose/upper throat, the nose and sinuses, or the salivary glands in the head and neck area
- Your cancer has spread to other parts of the body (distant spread)
- You have previously had radiotherapy to the head or neck area
- You have a pacemaker or an implanted defibrillator (a device that regulates your heartbeat)
- You have had another cancer in the last 5 years — though certain early-stage skin cancers and low-risk early-stage prostate cancer that were fully removed may not apply (confirm with trial site)
- You weigh more than 150 kg, due to equipment weight limits
- You have a serious or unstable medical or mental health condition that the trial doctor believes could affect your safety or ability to take part (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hanne Eide, MD PhD, Oslo University Hospital
Phone: 004722934000
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The combined burden of patient-reported dysphagia, xerostomia, pain and speech measured as the area under the curve (AUC) with EORTC QLQ-H&N43 at baseline, end of treatment, 3-, 6- and 12-months following radiotherapy.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.